The Victorian Racing Appeals and Disclinary Board hearing into the charges laid by the Racing Victoria Stewards' against licensed trainer Logan McGill will take place at 9.30am on Tuesday 26 June 2018.
Mr McGill has been charged as follows:
Charge 1 - AR 178
Subject to AR 178G, when any horse that has been brought to a racecourse for the purpose of engaging in a race and a prohibited substance is detected in any sample taken from it prior to or following its running in any race, the trainer and any other person who was in charge of such horse at any relevant time may be penalised.
The stewards allege that on 28 March 2018, Integrated was brought to Stony Creek racecourse and ran in the Bairs Hotel Leongatha Maiden Plate over 1100 metres. A prohibited substance, being Triamcinolone Acetonide (a corticosteroid), was detected in a post-race blood sample taken from Integrated on 28 March 2018.
Charge 2 - AR 178F
(1) A trainer must record treatment and medication administered to each horse in his or her care by midnight on the day on which the administration was given, and each record must include the following information:
(a) the name of the horse;
(b) the date and time of administration of the treatment or medication;
(c) the name of the treatment or medication administered (brand name or active constituent);
(d) the route of administration including by injection, stomach tube, paste, topical application or inhalation);
(e) the amount of medication given (if applicable);
(f) the duration of a treatment (if applicable);
(g) the name and signature of person or persons administering and/or authorizing the administration of the treatment or medication.
The stewards allege that on 14 March 2018, a veterinary practitioner engaged by Mr McGill, administered with his authority a medication, Kenacort (Triamcinolone Acetonide) and Hyaluronic Acid, to the knees and stifles of Integrated.
In accordance with AR 178F(1) Mr McGill failed to record in his treatment diary the following treatment and medication administered to Integrated on 14 March 2018:
a) the intra-articular injection of Kenacort and Hyaluronic Acid to the stifles; and
b) the amount of Kenacort and Hyaluronic Acid administered to the knees and stifles.